Status:
COMPLETED
A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Coronary Heart Disease
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This study will assess the effect of RO4607381, compared to placebo, on atherosclerotic plaque in patients with coronary heart disease (CHD) including patients with other CHD risk factors. After a pre...
Eligibility Criteria
Inclusion
- adult patients, 18-75 years of age;
- CHD, including patients with other CHD risk factors;
- treated appropriately for dyslipidemia;
- clinically stable.
Exclusion
- previous exposure to any cholesteryl ester transfer protein (CETP) inhibitor or vaccine;
- recent (within 3 months) clinically significant coronary events, transient ischemic attacks or cerebrovascular accident;
- severe anemia;
- uncontrolled hypertension;
- poorly controlled diabetes.
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00655473
Start Date
March 1 2008
End Date
November 1 2010
Last Update
January 3 2020
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Jacksonville, Florida, United States, 32216
2
Royal Oak, Michigan, United States, 48073
3
Minneapolis, Minnesota, United States, 55455
4
Kansas City, Missouri, United States, 64111